Agnete Kirkeby is associate professor, researcher and team lead at the University of Copenhagen (DK) and Lund University (S).
What do you do?
In short, my research focuses on stem cells and brain diseases such as Parkinson’s disease, Alzheimer’s disease, schizophrenia and dementia.
My research team and I have developed technologies that allow us to produce highly specialised human nerve cells from stem cells.
The new cell models can be used to imitate and gain a better understanding of diseases. They also allow us to test the effect of various drugs on human nerve cells.
What is the greater scope?
I hope to make a difference for patients suffering from neurodegenerative diseases and to propel research and development of drugs and treatment in the field.
Parkinson’s disease is one of our main focuses. We have developed a stem cell therapy for treatment of Parkinson’s disease that involves transplantation of new nerve cells into the brains of patients.
We also do research on Lewy body dementia, Alzheimer’s disease and schizophrenia in order to increase our knowledge of human brain diseases and the effect of drugs on patients.
In a recent project, we have produced appetite-regulating nerve cells to better understand the effect of weight-loss drugs such as Wegovy and Ozempic. We are also able to do drug screening – that is, to test new drugs – in our stem cell models. In other words, the cells help us understand how other hormones regulate our appetite and food intake.
Can you think of a big moment in your career?
For the past 13 years I have been responsible for the development of a stem cell treatment for Parkinson’s disease – from the first protocols to clinical production. In 2022, we received permission to test the treatment on humans. That was a big moment!
What do you enjoy the most about your job?
I love being a university researcher, because it allows me the freedom to pursue my own ideas and research interests.
It is not a nine-to-five, and though there is a tendency to work longer hours, the job is characterised by lovely flexibility and independence. You more or less make your own schedule, which has been extremely useful for me with three children at home.
As a university researcher I can pursue my ideas, my drive. You can think of it as academic entrepreneurship, where creative freedom goes hand in hand with stable conditions of employment and financial security.
What is the hardest part?
As a researcher and team lead I wear multiple hats, which would have been distributed across a number of people if I had worked in the private sector: scientific leader, student supervisor, staff manager, innovator, teacher, reviewer and external communicator – also of popular science.
It is fun, but challenging, because you have to balance and prioritise a number of tasks. I cannot focus 100 per cent on all aspects of my job; you have to be able to say no and prioritise.
How do you use your degree?
Human Biology gave me a broad understanding of human diseases. The programme included courses in pathophysiology, anatomy and pharmacology – subjects usually reserved for students of medicine.
The combination of cell biology and clinical insight provided me with a solid foundation for researching diseases and treatments. I gained a lot of knowledge during a clinical stay that involved patient interaction, and I still benefit from this knowledge.
Why did you choose to study human biology?
I did a bachelor’s degree in biochemistry because I wanted to focus on human diseases and molecular pathways of pathology. Right from the start, I had my eyes on the master’s degree programme in human biology, because I was interested in medicine, but did not want to become a doctor.
Human biology combines clinical insight with a research-oriented approach, and that appealed to me.
How did you arrive in your current position?
After completing the master’s degree programme in human biology, I did an industrial PhD at Lundbeck, which gave me insight into private-sector research.
This early encounter with the industry was very rewarding, and it also assured me in my decision to return to the university. It made it clear to me that I wanted to be free to pursue my own research ideas.
As a PhD student, I spent time at the Sloan Kettering Institute in New York. During that time, I gained an interest in stem cells, and it led me to do a postdoc at Lund University, which cemented my research interest in stem cells.
In 2017, I returned to the University of Copenhagen and a position as team lead at DanStem. Today, I am affiliated with reNEW (Novo Nordisk Foundation Center for Stem Cell Medicine).